Medical Training AIAnti-Obesity Medications Beyond GLP-1s
You'll be able to match non-GLP-1 anti-obesity medications to patient-specific factors like cost, needle aversion, intolerance, and comorbidities.
What this track covers
This track covers the anti-obesity pharmacotherapy landscape outside of GLP-1 receptor agonists, including oral agents, sympathomimetics, and combination products. It focuses on mechanism of action, patient selection, contraindications, and how these agents fit alongside or instead of GLP-1 therapy.
What you will practice
- Differentiate mechanisms of action across non-GLP-1 anti-obesity drug classes
- Select an agent based on cost, administration route, or needle aversion
- Screen for contraindications before starting a sympathomimetic or combination agent
- Choose an alternative mechanism for a patient who is GLP-1 intolerant
- Evaluate combination therapy options for a weight-loss plateau
Simulator scenario
A patient with a weight-loss plateau on an oral agent and a history of GLP-1 intolerance who is exploring combination therapy options.
Board question topics
- Mechanism of action of non-GLP-1 anti-obesity agents
- Contraindications and precautions by medication class
- Patient selection for oral versus combination therapy
- Managing plateaus with multi-mechanism approaches
Ask the tutor
The tutor only answers from licensed sources (FDA prescribing information, public guidelines and our own material) and says when it has none. Educational use only, never patient-specific advice.
Free during the beta. Sign in with your email, no password.
Start free